TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is expected to be releasing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect TG Therapeutics to post earnings of $0.24 per share and revenue of $152.1150 million for the quarter. TG Therapeutics has set its FY 2025 guidance at EPS.Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business’s quarterly revenue was up 92.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.04 earnings per share. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Stock Down 0.5%

Shares of NASDAQ TGTX opened at $33.33 on Monday. TG Therapeutics has a 12-month low of $22.92 and a 12-month high of $46.48. The firm’s 50-day simple moving average is $32.87 and its 200 day simple moving average is $34.94. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The company has a market cap of $5.29 billion, a price-to-earnings ratio of 90.08 and a beta of 1.97.

Analysts Set New Price Targets

TGTX has been the topic of a number of research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a research report on Saturday. B. Riley boosted their price objective on shares of TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. The Goldman Sachs Group upgraded TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Finally, HC Wainwright initiated coverage on TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 target price for the company. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.00.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.64% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently made changes to their positions in TGTX. EverSource Wealth Advisors LLC lifted its stake in TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 573 shares during the period. Geneos Wealth Management Inc. increased its stake in shares of TG Therapeutics by 200.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 2,169 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,446 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of TG Therapeutics by 9.6% in the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 665 shares during the period. HUB Investment Partners LLC boosted its stake in TG Therapeutics by 46.1% during the 2nd quarter. HUB Investment Partners LLC now owns 11,013 shares of the biopharmaceutical company’s stock worth $396,000 after acquiring an additional 3,477 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in TG Therapeutics by 221.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,166 shares of the biopharmaceutical company’s stock worth $438,000 after acquiring an additional 8,382 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.